Azixa
Novel Hsp90 Inhibitor to Begin Phase 1 Study in Cancer Patients
Submitted by Anonymous on Wed, 2009-04-08 17:22- Adrian Hobden
- apoptosis
- Azixa
- breast cancer
- Cancer
- cancer
- Cancer Treatment
- cancers
- chemical
- Clinical trial
- colon cancer
- Company Affiliates
- Company Ticker
- disease
- drug development
- Drug discovery
- FDA
- FDAPhase
- finance
- gastric cancer
- gastric cancers
- glioblastoma
- Health
- Health
- healthcare
- HIV
- Hsp90
- Hsp90
- Labor
- Labor
- lung cancer
- manufacturing
- Medicine
- melanoma
- metastasis
- MPC-3100
- MPC-4326
- multiple myeloma
- myeloid leukemia
- Myriad Genetics Inc.
- Myriad Pharmaceutical
- Myriad Pharmaceuticals Inc.
- Myriad Pharmaceuticals’ Development Programs Myriad Pharmaceuticals
- Occupational safety and health
- Pathology
- pharmacokinetics
- President
- Private
- Prostate cancer
- prostate cancer
- Salt Lake City
- Securities and Exchange Commission
- Social Issues
- Social Issues
- Technology
- Technology
- TopoTarget
- treatment of a wide range of cancers
- treatment of cancer
- treatment of HIV
- treatment of primary glioblastoma and melanoma
- tumor
- United States
- www.myriad.com
Salt Lake City April 8 2009 -- Myriad Pharmaceuticals Inc. announced today that the FDA has approved an Investigational New Drug (IND) application to begin a Phase 1 clinical study with its Hsp90 inhibitor MPC-3100 for the treatment of cancer. The clinical development plan for MPC-3100 is designed to expedite the drug candidate through the clinical development path. The Phase 1 trial will assess the safety and pharmacokinetics profile of MPC-3100.
»
- Read more
- 1956 reads
